{
    "ticker": "XFOR",
    "name": "X4 Pharmaceuticals, Inc.",
    "description": "X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for patients with rare diseases and conditions associated with immune system dysfunction. Founded in 2014 and headquartered in Cambridge, Massachusetts, X4 is dedicated to providing transformative medicines that can significantly improve the quality of life for patients. The company's lead product candidate, X4P-001, is an oral therapy designed to treat the underlying causes of rare diseases such as WHIM syndrome, a primary immunodeficiency. X4's innovative approach leverages its proprietary technology platform to target the chemokine receptor CXCR4, which plays a critical role in immune cell trafficking and function. The company is committed to advancing its clinical programs through rigorous research and collaboration with leading institutions. X4 Pharmaceuticals seeks to address significant unmet medical needs by harnessing the power of its scientific expertise and pipeline of drug candidates, aiming to create a healthier future for patients with challenging medical conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.x4pharma.com",
    "ceo": "Megan A. H. C. M. M. L. C. M. P. Clarkson",
    "social_media": {
        "twitter": "https://twitter.com/x4pharma",
        "linkedin": "https://www.linkedin.com/company/x4-pharmaceuticals/"
    },
    "investor_relations": "https://ir.x4pharma.com",
    "key_executives": [
        {
            "name": "Megan A. H. C. M. M. L. C. M. P. Clarkson",
            "position": "CEO"
        },
        {
            "name": "Richard G. Hargreaves",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "X4P-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "X4 Pharmaceuticals, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Learn about X4 Pharmaceuticals, Inc., a biotechnology company focused on developing transformative therapies for rare diseases. Explore our innovative pipeline and commitment to patient care.",
        "keywords": [
            "X4 Pharmaceuticals",
            "Biotechnology",
            "Rare Diseases",
            "CXCR4",
            "WHIM Syndrome",
            "X4P-001"
        ]
    },
    "faq": [
        {
            "question": "What does X4 Pharmaceuticals specialize in?",
            "answer": "X4 Pharmaceuticals specializes in developing novel therapies for rare diseases and conditions associated with immune system dysfunction."
        },
        {
            "question": "What is the lead product candidate of X4 Pharmaceuticals?",
            "answer": "The lead product candidate of X4 Pharmaceuticals is X4P-001, which targets WHIM syndrome."
        },
        {
            "question": "Where is X4 Pharmaceuticals headquartered?",
            "answer": "X4 Pharmaceuticals is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "When was X4 Pharmaceuticals founded?",
            "answer": "X4 Pharmaceuticals was founded in 2014."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "CRSP",
        "BMRN"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "JNJ"
    ]
}